A respected RNAi therapeutics company.

Acad. Sci.D., Professor of Internal Medicine and Molecular Genetics, University of Texas Southwestern Medical Center. Alnylam expects to progress its ALN-PCS plan toward the clinic with a goal of initiating a Stage I clinical trial in 2011. Source Alnylam Pharmaceuticals.. Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, today the presentation of new announced pre-medical data from its hypercholesterolemia plan, performed in collaboration with scientists at the University of Texas Southwestern Medical Center at Dallas.In the 1980s, he was one of the first physicians who recognized that mothers could transmit HIV with their newborns – and earned renown for treating children both in Newark and all over the world who faced inevitable death from AIDS. Fortunately, HIV/AIDS no longer takes many young lives, but kids born with severe types of muscular dystrophy and various other disorders – or badly wounded in shootings or incidents – continue steadily to endure unspeakable discomfort, and Oleske is usually their champion. Oleske's focus has become palliative care – relieving as much pain as possible for individuals in terrible situations. ‘Pain is a bad point,’ Oleske says, ‘and in the past as doctors we didn't recognize it.